Targeting DTX2 decreased the related histone epigenetic modifications of CXCL2 and CXCL6, thereby attenuating the immunosuppressive characteristics of the TME and sensitizing HCC cells to anti‐PD1 immunotherapy. The gene discussed is CXCL2; the disease is hepatocellular carcinoma.